Related Experiment Video
Updated: Jan 8, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Human genetics implicate thromboembolism in the pathogenesis of long COVID in individuals of European ancestry
Art Schuermans1,2,3, Andreas Verstraete4,5, Vilma Lammi6,7
1KU Leuven Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Leuven, Belgium. aschuerm@broadinstitute.org.
Insights
Genetic links between blood clots (thromboembolism) and long COVID provide new insights into the condition
Area of Science:
- Genetics
- Immunology
- Infectious Diseases
Background:
- Long COVID presents with diverse post-acute symptoms affecting multiple organs.
- Mechanisms for long COVID, such as inflammation and thromboembolism, lack robust human evidence.
- Causal links between SARS-CoV-2 infection and long COVID pathogenesis remain unclear.
Purpose of the Study:
- To investigate the association between genetic variants related to thromboembolism and the risk of developing long COVID.
- To identify potential molecular pathways contributing to long COVID through genetic analysis.
Main Methods:
- Utilized data from the Long COVID Host Genetics Initiative (3,018 cases, 994,582 controls).
- Employed Mendelian randomization to assess the causal effect of genetically predicted venous thromboembolism risk on long COVID.
- Conducted downstream analyses using gene-specific instruments and expression data.
Main Results:
- Increased genetically predicted venous thromboembolism risk was significantly associated with higher odds of long COVID (OR=1.21).
- This association remained independent of acute COVID-19 severity and was confirmed in external datasets.
- Protease-activated receptor 1 (PAR-1) was identified as a potential molecular contributor.
Conclusions:
- Human genetic evidence supports shared pathogenetic pathways between thromboembolism and long COVID.
- Findings suggest that thromboembolic processes may play a role in the development of long COVID.
- Identifies PAR-1 as a potential therapeutic target for long COVID.
Abstract:
SARS-CoV-2 infection can result in long COVID, characterized by post-acute symptoms from multiple organs. Current hypotheses on mechanisms underlying long COVID include persistent inflammation and thromboembolism; however, compelling evidence from humans is limited and causal associations remain unclear. In this study, we tested the association of thromboembolism-related genetic variants with long COVID in the Long COVID Host Genetics Initiative (ncases = 3,018; ncontrols = 994,582). Primary analyses revealed that each unit increase in the log odds of genetically predicted venous thromboembolism risk was associated with 1.21-fold odds of long COVID (95% confidence interval (CI): 1.08-1.35; P = 1.2 × 10-3). This association was independent of acute COVID-19 severity, was robust across various sensitivity analyses and was replicated in external datasets. Downstream analyses using gene-specific instruments, along with protein and gene expression data, suggested the protease-activated receptor 1 (PAR-1) as a potential molecular contributor to long COVID. These findings provide human genetic evidence implicating shared pathogenetic pathways in thromboembolism and long COVID.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Single Nucleotide Polymorphisms-SNPs
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

